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Abstract
Cancer arises from a series of genetic and epigenetic changes, which result in abnormal expression or mutational
activation of oncogenes, as well as suppression/inactivation of tumor suppressor genes. Aberrant expression of
coding genes or long non-coding RNAs (lncRNAs) with oncogenic properties can be caused by translocations, gene
amplifications, point mutations or other less characterized mechanisms. One such mechanism is the inappropriate
usage of normally dormant, tissue-restricted or cryptic enhancers or promoters that serve to drive oncogenic gene
expression. Dispersed across the human genome, endogenous retroviruses (ERVs) provide an enormous reservoir of
autonomous gene regulatory modules, some of which have been co-opted by the host during evolution to play
important roles in normal regulation of genes and gene networks. This review focuses on the “dark side” of such
ERV regulatory capacity. Specifically, we discuss a growing number of examples of normally dormant or epigenetically
repressed ERVs that have been harnessed to drive oncogenes in human cancer, a process we term onco-exaptation,
and we propose potential mechanisms that may underlie this phenomenon.
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Background
Sequences derived from transposable elements (TEs) oc-
cupy at least half the human genome [1, 2]. TEs are gen-
erally classified into two categories; DNA transposons,
which comprise 3.2% of the human genome; and the ret-
roelements, short interspersed repeats (SINEs, 12.8% of
the genome), long interspersed repeats (LINEs, 20.7%)
and long terminal repeat (LTR) elements, derived from
endogenous retroviruses (ERVs, 8.6%). Over evolutionary
time, TE sequences in the genome can become func-
tional units that confer a fitness advantage, a process
called “exaptation” [3, 4]. Exaptation includes protein
coding, non-coding and regulatory effects of TEs. This is
in contrast to the designation of “nonaptations” for gen-
etic units that perform some function (such as initiate
transcription) but don’t impact host fitness [4]. Besides
their roles in shaping genomes during evolution, TEs
continue to have impact in humans through insertional
mutagenesis, inducing rearrangements and affecting gene
regulation, as discussed in recent reviews [5–12].
Efforts to explore the role of TEs in human cancer
have focused primarily on LINEs and ERVs. While nearly
all L1s, the major human LINE family, are defective, a
few hundred retain the ability to retrotranspose [13] and
these active elements occasionally cause germ line muta-
tions [9, 14, 15]. Several recent studies have also docu-
mented somatic, cancer-specific L1 insertions [16–23],
and a few such insertions were shown to contribute to
malignancy [9]. For example, two L1 insertions were
documented to disrupt the tumor suppressor gene APC
in colon cancer [16, 23]. However, it is probable that
most insertions are non-consequential “passenger muta-
tions”, as recently discussed by Hancks and Kazazian [9].
Thus, the overall biological effect size of LINE retrotran-
sposition on the process of oncogenesis may be limited.
No evidence for retrotranspositionally active ERVs in
humans has been reported [24–26], so it is unlikely that
human ERVs activate oncogenes or inactivate tumor
suppressor genes by somatic retrotransposition. This is
in contrast to the frequent oncogene activation by inser-
tions of exogenous and endogenous retroviruses in
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chickens or mice, where retrotranspositional activity of
ERVs is very high [27–29]. Therefore, to date, most stud-
ies into potential roles for ERVs in human cancer have
focused on their protein products. Indeed, there is
strong evidence that the accessary proteins Np9 and
Rec, encoded by members of the relatively young HERV-
K (HML-2) group, have oncogenic properties, particu-
larly in germ cell tumors [30–33].
Regardless of their retrotranspositional or coding cap-
acity, ERVs may play a broader role in oncogenesis involv-
ing their intrinsic regulatory capacity. De-repression/
activation of cryptic (or normally dormant) promoters to
drive ectopic expression is one mechanism that can lead
to oncogenic effects [34–40]. Because TEs, and especially
ERV LTRs, are an abundant reservoir of natural pro-
moters in the human genome [6, 41, 42], inappropriate
transcriptional activation of typically repressed LTRs may
contribute to oncogenesis. Here we review examples of
such phenomena, which we term “onco-exaptation”, and
propose two explanatory models to understand the role of
LTRs in oncogenesis.
Promoter potential of ERVs
Hundreds of ERV “families” or groups, which is the
more proper designation [43], are remnants of ancient
retroviral infections of the germ line and occupy at least
8.67% of the human genome [1, 24, 44]. These range
from groups that integrated before the divergence of ro-
dents and primates, such as older members of the large
MaLR/ERV-L class, to the youngest HERV-K (HML-2)
group, a few members of which are insertionally poly-
morphic in humans [45, 46]. While it has been postu-
lated that rare “active” HERV-K elements exist at very
low allele frequencies [45], there is currently no evi-
dence for new somatic or germ line insertions of ERVs
in humans and nearly all have lost coding potential
[24–26]. The situation is starkly different in inbred
mice, where at least 10% of documented, phenotype-
producing germ line mutations and numerous somatic,
cancer-associated insertions are due to ongoing retro-
transpositions of ERVs [28, 29, 47]. Table 1 lists select
major ERV groups found in humans, members of which
are mentioned in this review.
Approximately 90% of the “ERV-related” human gen-
omic DNA is in the form of solitary LTRs, which are cre-
ated over evolutionary time via recombination between
the 5’ and 3’ LTRs of an integrated provirus [48, 49].
LTRs naturally contain transcriptional promoters and
enhancers, and often splice donor sites, required for au-
tonomous expression of the integrated LTR element.
Furthermore, unlike for LINEs (see below), the integra-
tion process nearly always retains the primary tran-
scriptional regulatory motifs, i.e. the LTR, even after
recombination between the LTRs of a full-length proviral
form. Mutations will degrade LTR promoter/enhancer
motifs over time, but many of the >470,000 ERV/LTR loci
in the genome [50] likely still retain some degree of their
ancestral promoter/enhancer function, and hence a gene
regulatory capacity.
LTR-mediated regulation of single genes and gene net-
works has been increasingly documented in the litera-
ture. For example, studies have implicated ERV LTRs in
species-specific regulatory networks in ES cells [51], in
the interferon response [52], in p53-mediated regulation
[53], as tissue-specific enhancers [54, 55] and in regulat-
ing pluripotency by promoting genes and lncRNAs in
stem cells [56–60]. LTR regulatory capacity arises from
both their “ready-to-use” ancestral transcriptional factor
(TF) binding sites and by mutation/evolution of novel
sites, possibly maintained through epistatic capture [61]
(recently reviewed in [42]). For more in depth discussion
of the evolutionary exaptation of enhancers/promoters
of LTRs and other TEs in mammals, we refer the reader
to a rapidly growing number of reviews on this subject
Table 1 ERV/LTR groups mentioned in this review
ERV Class ERV Group Associated LTRs (Repbase names) ~Copies of internal regionsa ~Copies of solitary LTRsb
I (ERV1) HERV-H LTR7, 7B, 7C, 7Y 1060 1270
HERV-9 LTR12, 12B-12 F 450 6500
HERV-E LTR2, 2B, 2C 250 720
HUERS-P2 LTR1, 1A-1 F 120 3000
LOR1 LOR1a, 1b 175 1080
MER41 MER41A-41G 275 4110
II (ERVK) HERV-K (HML-2) LTR5, 5A, 5B, 5Hs 80 1200
III (ERVL) HERV16 LTR16A-16E 860 18100
III (MaLR) THE THE1A-1D 7900 21260
MLT1 MLT1A-1O 3820 146,550
aCopy numbers of internal regions estimated from Dfam (dfam.org) [50]
bSolitary LTR numbers estimated from Dfam coverage minus 2x internal region numbers, assuming all internal regions are associated with two LTRs
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[6, 10, 42, 62–65]. Suffice it to say that, retrotransposi-
tionally incompetent ERV LTRs, long considered the
“poor cousin” of active L1 elements, have emerged from
the shadowy realm of junk DNA and are now recognized
as a major source of gene regulatory evolution through
exaptation of their promoters and enhancers.
Promoter potential of LINEs and other non-LTR TEs
Besides via new retrotransposition events, existing L1 el-
ements can also impact genes through promoter dona-
tion. Full-length L1 elements harbor two internal
promoters at their 5’ end, a sense promoter that drives ex-
pression of the element and an antisense promoter that
has been shown to control expression of nearby genes
through formation of chimeric transcripts [66–69]. Re-
cently, this antisense promoter was also shown to promote
expression of a small protein ORF0, which plays a regula-
tory role in retrotransposition [70]. While there are ap-
proximately 500,000 L1 loci in the human genome [1], the
vast majority of them are 5’ truncated due to incomplete
reverse transcription during the retrotransposition
process. Only ~3500-7000 are full length, retaining their
promoters and hence, the potential ability to lend these
promoters to nearby genes [71, 72]. Therefore, irrespective
of differences in promoter strength, epigenetic regulation
or mutational degradation, the vast copy number differ-
ence (~500,000 LTRs versus ~5000 promoter-containing
L1s), is likely a major reason why the great majority of
TE-initiated transcripts involve LTRs rather than L1s. In
genome-wide screens of TE-initiated transcripts, small
fragments of old L2 elements, which do not span the ca-
nonical L2 promoter, can be found as TSSs of lowly
expressed transcripts [73] (unpublished data). Such in-
stances likely represent “de novo” promoters, those arising
naturally from genomic DNA which happens to be de-
rived from a TE fragment, (possibly because L2 fragments
have a GC rich base composition), rather than an “ances-
tral” or “ready-made” promoter, one which utilizes a TE’s
original regulatory sequence.
Human SINE elements, namely ALUs and the older
MIRs, can also promote transcription of nearby genes
but these instances are relatively rare [68] given their ex-
tremely high copy numbers (~1.85 million fragments)
[50]. This likely partly reflects the fact that SINEs, being
derived from small functional RNAs, inherently possess
PolIII promoters, rather than PolII, and their autono-
mous promoter strength is weak [74, 75]. Old MIR ele-
ments, as well as other ancient SINEs and DNA TEs,
have been more prominent as enhancers, rather than
genic promoters, as shown in several studies [76–81].
TEs and the cancer transcriptome
While some TE components have assumed cellular func-
tions over evolutionary time, such as the syncytin genes
in mammalian placenta, derived from independent ERV
env genes in multiple mammals [6, 44, 82–84], the vast
majority of TE/ERV insertions will be neutral or detri-
mental to the host. Given the potential for harm, mul-
tiple host mechanisms to repress these sequences have
evolved. In mammals, ERV and L1 transcription is sup-
pressed in normal cells by DNA methylation and/or
histone modifications as well as many other host fac-
tors [9, 85–92]. The epigenetic regulation of TEs is
relevant in cancer because epigenetic changes are com-
mon in malignancy and frequently associated with mu-
tations in “epigenome-modifying” genes [93–97]. While
the ultimate effects of many such mutations are not yet
clear, their prominence indicates a central role for epi-
genomic dysregulation in oncogenesis [94, 98]. The
most well established epigenetic changes are promoter
hypermethylation and associated silencing of tumor
suppressor genes [95, 99, 100] as well as genome-wide
DNA hypomethylation [101–103]. Hypomethylation of
ERVs and L1s in many tumors has been documented
[104–106] and general transcriptional up-regulation of
ERVs and L1s is often observed in cancers [33, 107–109].
However, other studies have shown no significant changes
in ERV expression in selected human cancers compared
to corresponding normal tissues [110, 111].
General conclusions about overall TE transcriptional
deregulation in malignancy, or in any other biological
state, are not always well founded and can depend on
the type and sensitivity of the assay. For example, ex-
pression studies that use consensus probes for internal
L1 or ERV regions to assay expression by custom micro-
arrays or RT-PCR don’t resolve individual loci, so high
expression signals could reflect dispersed transcriptional
activation of many elements or the high expression of
only one or a few loci. Such assays typically also cannot
distinguish between expression due to TE promoter de-
repression or due to increased transcription of tran-
scripts harboring TEs. RNA-Seq has the potential to give
information on expression of individual TE loci, but in-
terpretations of expression levels can be confounded by
mapping difficulties, length of read and sequencing
depth [112]. In any event, in most cases where transcrip-
tional up-regulation of TE groups or individual TEs has
been detected in cancer, the biological relevance of such
aberrant expression is poorly understood.
Onco-exaptation of ERV/TE promoters
We propose that transcriptional up-regulation of LTR
(and to a lesser extent L1) promoters is widespread in
epigenetically perturbed cells such as cancer cells. Here
we present specific published examples of onco-
exaptation of TE-derived promoters affecting protein-
coding genes (Table 2, Fig. 1). Although many other
TE-initiated transcripts have been identified in cancer
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cells (see below), in this section we restrict the discus-
sion to those cases where some role of the TE-driven
gene in cancer or cell growth has been demonstrated.
Ectopic and overexpression of protein-coding genes
The most straightforward interaction between a TE pro-
moter and a gene is when a TE promoter is activated,
initiates transcription, and transcribes a downstream
gene without altering the open reading frame (ORF),
thus serving as an alternative promoter. Since the TE
promoter may be regulated differently than the native
promoter, this can result in ectopic and/or overexpres-
sion of the gene, with oncogenic consequences.
The first case of such a phenomenon was discovered
in the investigation of a potent oncogene colony stimu-
lating factor one receptor (CSF1R) in Hodgkin Lymph-
oma (HL). Normally, CSF1R expression is restricted to
macrophages in the myeloid lineage. To understand how
this gene is expressed in HL, a B-cell derived cancer,
Lamprecht et al. [113] performed 5’ RACE which re-
vealed that the native, myeloid-restricted promoter is si-
lent in HL cell lines, with CSF1R expression instead
being driven by a solitary THE1B LTR, of the MaLR-
ERVL class (Fig. 1a). THE1B LTRs are ancient, found in
both Old and New World primates, and are highly
abundant in the human genome, with a copy number of
~17,000 [50, 114] (Table 1). The THE1B-CSF1R tran-
script produces a full-length protein in HL, which is re-
quired for growth/survival of HL cell lines [113] and is
clinically prognostic for poorer patient survival [115].
Ectopic CSF1R expression in HL appears to be com-
pletely dependent on the THE1B LTR, and CSF1R pro-
tein or mRNA is detected in 39–48% of HL patient
samples [115, 116].
To detect additional cases of onco-exaptation, we
screened whole transcriptomes (RNA-Seq libraries) from
a set of HL cell lines as well as from normal human B
cells for TE-initiated transcripts, specifically transcripts
that were recurrent in HL and not present in normal B
cells [117]. We identified the Interferon Regulatory
Factor 5 gene (IRF5) as a recurrently up-regulated gene
being promoted by a LOR1a LTR located upstream of
the native/canonical TSS (Fig. 1b). LOR1a LTRs are
much less abundant compared to THE1 LTRs (Table 1)
but are of similar age, with the IRF5 copy having
inserted prior to New World-Old World primate diver-
gence. IRF5 has multiple promoters/TSSs and complex
transcription [118] and, contrary to the CSF1R case, the
native promoters are not completely silent in HL. How-
ever, LTR activity correlates with strong overexpression
of the IRF5 protein and transcript, above normal physio-
logical levels [117]. While our study was ongoing, Kreher
et al. reported that IRF5 is upregulated in HL and is a
central regulator of the HL transcriptome [119]. More-
over, they found that IRF5 is crucial for HL cell survival.
Intriguingly, we noted that insertion of the LOR1a LTR
created an interferon regulatory factor-binding element
(IRFE) that overlaps the 5’ end of the LTR. This IRFE
was previously identified to be critical for promoter ac-
tivity as a positive feedback loop through binding of
various IRFs, including IRF5 itself [120]. Hence, the in-
herent promoter motifs of the LTR, coupled with the
creation of the IRFE upon insertion, combined to pro-
vide an avenue for ectopic expression of IRF5 in HL.
Expression of truncated proteins
In these cases, a TE-initiated transcript results in the ex-
pression of a truncated open reading frame of the af-
fected gene, typically because the TE is located in an
intron, downstream of the canonical translational start
site. The TE initiates transcription, but the final tran-
script structure depends on the position of downstream
splice sites, and protein expression requires usage of a
downstream ATG. Protein truncations can result in
oncogenic effects due to loss of regulatory domains or
through other mechanisms, with a classic example being
Table 2 Activation of oncogenes by Onco-exaptation of TE-derived promoters
Genea Gene function Primary result of TE-driven
expression
TE type TE promoter coordinates
(hg38)
Cancer type references
CSF1R Tyrosine kinase receptor Ectopic expression of
normal protein
(ERVL-MaLR) THE1B LTR chr5:150092453–150092809 HL [113]
IRF5 Transcription factor Ectopic expression of
normal protein
(ERV1) LOR1a LTR chr7:128936859–128937097 HL [117, 119]
MET Tyrosine kinase receptor Protein truncation (L1) L1PA2 chr7:116718498–116724489 CML, others? [124, 125]
ALK Tyrosine kinase receptor Protein truncation (ERVL) LTR16B2 chr2:29223783–29224196 melanoma [38]





SLCO1B3 Anion transporter Chimeric protein (ERV1) LTR7b chr12:20822187–20822617 colon, others [133, 136]
FABP7 Fatty acid binding Chimeric protein (ERV1) LTR2 chr6:122748805–122749262 DLBCL [138]
aOnly those cases with supporting evidence of a role in the cancer are listed
bThe fact that the promoter for these isoforms is an LTR was not noted in the cited papers
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v-myb, a truncated form of myb carried by acutely trans-
forming animal retroviruses [121, 122].
The first such reported case involving a TE was identi-
fied in a screen of human ESTs to detect transcripts
driven by the antisense promoter within L1 elements.
Mätlik et al. identified an L1PA2 within the second in-
tron of the proto-oncogene MET (MET proto-oncogene,
receptor tyrosine kinase) that initiates a transcript by
splicing into downstream MET exons (Fig. 1c) [67]. Not
surprisingly, transcriptional activity of the CpG rich pro-
moter of this L1 in bladder and colon cancer cell lines is
inversely correlated to its degree of methylation [123, 124].
A slightly truncated MET protein is produced by the TE-
initiated transcript and one study reported that L1-driven
transcription of MET reduces overall MET protein levels
and signaling, although by what mechanism is not clear
[124]. Analyses of normal colon tissues and matched pri-
mary colon cancers and liver metastasis samples showed
this L1 is progressively demethylated in the metastasis
samples, which strongly correlates with increased L1-MET
transcripts and protein levels [125]. Since MET levels are a
negative prognostic indicator for colon cancer [126], these
findings suggest an oncogenic role for L1-MET.
More recently, Wiesner et al. identified a novel iso-
form of the receptor tyrosine kinase (RTK), anaplastic
lymphoma kinase (ALK), initiating from an alternative
promoter in its 19th intron [38]. This alternative tran-
scription initiation (ATI) isoform or ALKATI was re-
ported to be specific to cancer samples and found in
~11% of skin cutaneous melanomas. ALKATI transcripts
produce three protein isoforms encoded by exons 20 to
29. These smaller isoforms exclude the extracellular do-
main of the protein but contain the catalytic intracellular
tyrosine kinase domain. This same region of ALK is
commonly found fused with a range of other genes via
chromosomal translocations in lymphomas and a variety
of solid tumors [127]. In the Wiesner et al. study it was
found that ALKATI stimulates several oncogenic signal-
ing pathways, drives cell proliferation in vitro, and pro-
motes tumor formation in mice [38].
The ALKATI promoter is a sense-oriented solitary LTR
(termed LTR16B2) derived from the ancient ERVL fam-
ily (Fig. 1d). LTR16B2 elements are found in several
hundred copies in both primates and rodents [50, 114]
and this particular element is present in the orthologous
position in mouse. Therefore, the promoter potential of
this LTR has been retained for at least 70 million years.
Although not the first such case, the authors state that
their findings “suggest a novel mechanism of oncogene
activation in cancer through de novo alternative tran-
script initiation”. Evidence that this LTR is at least occa-
sionally active in normal human cells comes from
Capped Analysis of Gene Expression (CAGE) analysis
through the FANTOM5 project [128]. A peak of CAGE
tags from monocyte-derived macrophages and endothe-
lial progenitor cells occurs within this LTR, 60 bp down-
stream of the TSS region identified by Wiesner et al.
[38] (Fig. 2a), although a biological function, if any, of
this isoform in normal cells is unknown.
To gain a molecular understanding of ALK-negative
anaplastic large-cell lymphoma (ALCL) cases, Scarfo et
al. conducted gene expression outlier analysis and identi-
fied high ectopic co-expression of ERBB4 and COL29A1
in 24% of such cases [129]. Erb-b2 receptor tyrosine kin-
ase 4 (ERBB4), also termed HER4, is a member of the
ERBB family of RTKs, which includes EGFR and HER2,
and mutations in this gene have been implicated in
some cancers [130]. Analysis of the ERRB4 transcripts
expressed in these ALCL samples revealed two iso-
forms initiated from alternative promoters, one within
intron 12 (I12-ERBB4) and one within intron 20 (I20-
ERBB4), with little or no expression from the native/
canonical promoter. Both isoforms produce truncated
proteins that show oncogenic potential, either alone
(See figure on previous page.)
Fig. 1 Examples of Onco-exaptation. Gene models of known TE-derived promoters expressing downstream oncogenes and listed in Table 2.
Legend is shown at the top. a 6 kb upstream of CSF1R, a THE1B LTR initiates transcription and contains a splice donor site which joins to an exon
within a LINE L1MB5 element and then into the first exon of CSF1R. The TE-initiated transcript has a different, longer 5’ UTR than the canonical
transcript but the same full-length protein coding sequence. b An LOR1a LTR initiates transcription and splices into the canonical second exon of
IRF5 that contains the standard translational initiation site (TIS) to produce a full-length protein. There also is a novel second exon which is non-
TE derived which is incorporated into a minor isoform of LOR1a-IRF5. c Within the canonical intron 2 of the proto-oncogene MET, a full length
LINE L1PA2 element initiates transcription (anti-sense to itself), splicing through a short exon in a SINE MIR element and into the third exon of
MET. The first TIS of the canonical MET transcript is 14 bp into exon 2, although an alternative TIS exists in exon 3, which is believed to also be
used by the L1-promoterd isoform. d An LTR16B2 element in intron 19 of the ALK gene initiates transcription and transcribes into the canonical
exon 20 of ALK. An in-frame TIS within the 20th exon results in translation of a shortened oncogenic protein containing only the intra-cellular
tyrosine kinase domain, but lacking the transmembrane and extracellular receptor domains of ALK. e There are two TE-promoted isoforms of
ERBB4, the minor variant initiates in an MLT1C LTR in the 12th intron and the major variant initiates in a MLT1H LTR in the 20th intron. Both
isoforms produce a truncated protein, although the exact translation start sites are not defined. f In the third exon of SLCO1B3, two adjacent partly
full-length HERV elements conspire to create a novel first exon. Transcription initiates in the anti-sense orientation from an LTR7 and
transcribes to a sense-oriented splice donor in an adjacent MER4C LTR, which then splices into the fourth exon of SLCO1B3, creating a smaller
protein. g An LTR2 element initiates anti-sense transcription (relative to its own orientation) and splices into the native second exon of FABP7. The
LTR-derived isoform has a non-TE TIS and splice donor which creates a different N-terminal protein sequence of FABP7
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(I12 isoform) or in combination. Remarkably, both
promoters are LTR elements of the ancient MaLR-
ERVL class (Fig. 1e). Of note, Scarfo et al. reported
that two thirds of ERBB4 positive cases showed a
“Hodgkin-like” morphology, which is normally found
in only 3% of ALCLs [129]. We therefore examined
our previously published RNA-Seq data from 12 HL
cell lines [117] and found evidence for transcription
from the intron 20 MLTH2 LTR in two of these lines
(unpublished observations), suggesting that truncated
ERBB4 may play a role in some HLs.
TE-promoted expression of chimeric proteins
Perhaps the most fascinating examples of onco-exaptation
involve generation of a novel “chimeric” ORF via usage of
a TE promoter that fuses otherwise non-coding DNA to
downstream gene exons. These cases involve both protein
and transcriptional innovation and the resulting product
can acquire de novo oncogenic potential.
The solute carrier organic anion transporter family
member 1B3, encodes organic anion transporting poly-
peptide 1B3 (OATP1B3, or SLCO1B3), is a 12-
transmembrane transporter with normal expression
and function restricted to the liver [131]. Several
studies have shown that this gene is ectopically
expressed in solid tumors of non-hepatic origin, par-
ticularly colon cancer [131–134]. Investigations into
the cause of this ectopic expression revealed that the
normal liver-restricted promoter is silent in these can-
cers, with expression of “cancer-type” (Ct)-OATP1B3
being driven from an alternative promoter in the sec-
ond canonical intron [133, 134]. While not previously
reported as being within a TE, we noted that this alter-
native promoter maps within the 5’ LTR (LTR7) of a
partly full-length antisense HERV-H element that is
missing the 3’ LTR. Expression of HERV-H itself and
LTR7-driven chimeric long non-coding RNAs is a
noted feature of embryonic stem cells and normal early
embryogenesis, where several studies indicate an intri-
guing role for this ERV group in pluripotency (for re-
cent reviews see [8, 10, 60]). A few studies have also
noted higher general levels of HERV-H transcription in
colon cancer [109, 135]. The LTR7-driven isoform of
SLCO1B3 makes a truncated protein lacking the first
28 amino acids but also includes protein sequence
from the LTR7 and an adjacent MER4C LTR (Fig. 1f ).
The novel protein is believed to be intracellular and its
role in cancer remains unclear. However, one study
Fig. 2 a UCSC Genome Browser view (hg19) of a portion of the human ALK gene. ALK exon 20 (large blue box) and a part of the upstream
intron are shown, with direction of transcription from right to left. The LTR16B2 alternative promoter shown in the Repeatmasker track as an
orange box and the 25 bp region of clustered TSSs in melanoma cells, identified using 5’ RACE by Weiser et al. [38], is shown as a green box The
CAGE track above is from the Fantom5 project [128], with transcriptional direction indicated with a blue arrow. Most CAGE tags are from
monocyte-derived macrophages and endothelial progenitor cells. b UCSC Genome Browser view (hg19) of the region encompassing the SAMMSON
lncRNA, which plays an oncogenic role in melanoma [161]. The LTR1A2 promoter is indicated in the Repeatmasker track as an orange box.
The ChIP-Seq track for SOX10 was created from a dataset (NCBI Gene Expression Omnibus: GSE61967) generated by Laurette et al. [225] in the
501Mel melanoma cell line
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showed that high expression of this isoform is corre-
lated with reduced progression-free survival in colon
cancer [136].
In another study designed specifically to look for TE-
initiated chimeric transcripts, we screened RNA-seq li-
braries from 101 patients with diffuse large B-cell
lymphoma (DLBCL) of different subtypes [137] and
compared to transcriptomes from normal B-cells. This
screen resulted in the detection of 98 such transcripts
that were found in at least two DLBCL cases and no
normals [138]. One of these involved the gene for
fatty acid binding protein 7 (FABP7). FABP7, nor-
mally expressed in brain, is a member of the FABP
family of lipid chaperones involved in fatty acid up-
take and trafficking [139]. Overexpression of FABP7
has been reported in several solid tumor types and is
associated with poorer prognosis in aggressive breast
cancer [139, 140]. In 5% of the DLBCL cases
screened, we found that FABP7 is expressed from an
antisense LTR2 (the 5’LTR of a HERV-E element)
(Fig. 1g). Since the canonical ATG is in the first exon
of FABP7, the LTR driven transcript encodes a
chimeric protein with a different N-terminus (see ac-
cession NM_001319042.1) [138]. Functional analysis
in DLBCL cell lines revealed that the LTR-FABP7
protein isoform is required for optimal cell growth
and also has subcellular localization properties dis-
tinct from the native form [138].
Overall, among all TE types giving rise to chimeric
transcripts detected in DLBCL, LTRs were over repre-
sented compared to their genomic abundance and,
among LTR groups, we found that LTR2 elements and
THE1 LTRs were over represented [138]. As discussed
above, this predominance of LTRs over other TE types
is expected.
TE-initiated non-coding RNAs in cancer
Since TEs, particularly ERV LTRs, provide a major class
of promoters for long non-coding RNAs [56, 141, 142],
it is not surprising that multiple LTR-driven lncRNAs
have been shown to be involved in cancer. These cases
can be broadly divided into those with direct, measur-
able oncogenic properties (Table 3) and those with ex-
pression correlated with a cancer. It should be noted
that we have likely missed some examples if the nature
of the promoter was not highlighted or mentioned in
the original publications. Unlike the coding genes dis-
cussed above which have non-TE or native promoters in
normal tissues, the lncRNAs described here typically
have LTRs as their only promoter in normal or malig-
nant cells.
TE-initiated LncRNAs with oncogenic properties
In an extensive study, Prensner et al. reported that the
lncRNA SchLAP1 (SWI/SNF complex antagonist associ-
ated with prostate cancer 1) is overexpressed in ~25% of
prostate cancers, is an independent predictor of poor
clinical outcomes and is critical for invasiveness and me-
tastasis [143]. Intriguingly, they found that SchLAP1 in-
hibits the function of the SWI/SNF complex, which is
known to have a tumor suppressor roles [144]. While
not mentioned in the main text, the authors report in
supplementary data that the promoter for this lncRNA
is an LTR (Fig. 3a). Indeed, this LTR is a sense-oriented
solitary LTR12C (of the ERV9 group).
Linc-ROR is a non-coding RNA (long intergenic non-
protein coding RNA, regulator of reprogramming) pro-
moted by the 5’ LTR (LTR7) of a full length HERV-H
element [56] (Fig. 3b) and has been shown to play a role
in human pluripotency [145]. Evidence suggests it acts
as a microRNA sponge of miR-145, which is a repressor
of the core pluripotency transcription factors Oct4,
Nanog and Sox2 [146]. Several recent studies have re-
ported an oncogenic role for Linc-ROR in different can-
cers by sponging miR-145 [147–149] or through other
mechanisms [150, 151].
Using Serial Analysis of Gene Expression (SAGE),
Rangel et al. identified five Human Ovarian cancer Spe-
cific Transcripts (HOSTs) that were expressed in ovarian
cancer but not in other normal cells or cancer types
Table 3 LTR-driven LncRNAs with oncogenic role
lncRNAa TE type TE promoter coordinates (hg38) Cancer type references
SchLAP1 (ERV1) LTR12C chr2:180691205–180692425 prostate [143]
ROR (ERV1) LTR7 chr18:57072052–57072502 breast, others [147, 150]
HOST2 (ERV1) LTR2B chr10:84171987–84172465 ovarian [154]
AFAP1-AS1 (ERVL-MaLR) THE1A LTRb chr4:7753884–7754236 several [156, 158]
SAMMSON (ERV1) LTR1A2b chr3:69999501–70000359 melanoma [161]
HULC (ERVL-MaLR) MLT1A LTR chr6:8652095–8652454 liver [163]
UCA1 (ERV1) LTR7C chr19:15828738–15829200 several [165, 167]
BANCR (ERV1) MER41B LTR chr9:69306939–69307567 melanoma, others [169]
aOnly those cases with supporting evidence of a role in the cancer are listed
bThe fact that the promoter is an LTR was not previously noted
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examined [152]. One of these, HOST2, is annotated as a
spliced lncRNA entirely contained within a full length
HERV-E and promoted by an LTR2B element (Fig. 3c).
Perusal of RNA-Seq from the 9 core ENCODE cell lines
shows robust expression of HOST2 in GM12878, a B-
lymphoblastoid cell line, which extends beyond the
HERV-E. As with Linc-ROR, HOST2 appears to play an
oncogenic role by functioning as a miRNA sponge of
miRNA let-7b, an established tumor suppressor [153], in
epithelial ovarian cancer [154].
The Ref-Seq annotated lncRNA AFAP1 antisense RNA
1 (AFAP1-AS1) runs antisense to the actin filament asso-
ciated protein 1 (AFAP1) gene and several publications
report its up-regulation and association with poor sur-
vival in a number of solid tumor types [155–158]. While
the oncogenic mechanism of AFAP1-AS1 has not been
extensively studied, one report presented evidence that it
promotes cell proliferation by upregulating RhoA/Rac2
signaling [159] and its expression inversely correlates
with AFAP1. Although clearly annotated as initiating
within a solitary THE1A LTR (Fig. 3d), this fact has not
been mentioned in previous publications. In screens for
TE-initiated transcripts using RNA-seq data from HL
cell lines, we noted recurrent and cancer-specific up-
regulation of AFAP1-AS1 (unpublished observations),
suggesting that it is not restricted to solid tumors. The
inverse correlation of expression between AFAP1 and
AFAP1-AS1 suggests an interesting potential mechanism
by which TE-initiated transcription may suppress a gene;
where an anti-sense TE-initiated transcript disrupts the
transcription, translation or stability of a tumor suppres-
sor gene transcript through RNA interference [160].
Fig. 3 Gene models of select lncRNAs initiating within LTRs that are involved in oncogenesis. a A solitary LTR12C element initiates SChLAP1, a
long inter-genic non-coding RNA. b The 5’ LTR7 of a full-length HERVH element initiates the lncRNA ROR, with an exon partially incorporating
internal ERV sequence. c The HOST2 lncRNA is completely derived from components of a Harlequin (or HERV-E) endogenous retrovirus and its
flanking LTR2B. d Anti-sense to the AFAP1 gene, a THE1A LTR initiates transcription of the lncRNA AFAP1-AS1. The second exon of AFAP1-AS1
overlaps exons 14–16 of AFAP1, possibly leading to RNA interference of the gene
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The SAMMSON lncRNA (survival associated mito-
chondrial melanoma specific oncogenic non-coding
RNA), which is promoted by a solitary LTR1A2 element,
was recently reported as playing an oncogenic role in
melanoma [161]. This lncRNA is located near the
melanoma-specific oncogene MITF and is always in-
cluded in genomic amplifications involving MITF. Even
in melanomas with no genomic amplification of this
locus, SAMMSON is expressed in most cases, increases
growth and invasiveness and is a target for SOX10 [161],
a key TF in melanocyte development which is deregu-
lated in melanoma [162]. Interestingly, the two SOX10
binding sites near the SAMMSON TSS lie just upstream
and downstream of the LTR (Fig. 2b), suggesting that
both the core promoter motifs provided by the LTR and
adjacent enhancer sites combine to regulate SAMMSON.
Other examples of LTR-promoted oncogenic lncRNAs
include HULC for Highly Upregulated in Liver Cancer
[163, 164], UCA1 (urothelial cancer associated 1)
[165–168] and BANCR (BRAF-regulated lncRNA 1)
[169–171]. Although not mentioned in the original
paper, three of the four exons of BANCR were shown
to be derived from a partly full length MER41 ERV,
with the promoter within the 5’LTR of this element
annotated MER41B [141]. Intriguingly, MER41 LTRs
were recently shown to harbor enhancers responsive
to interferon, indicating a role for this ERV group in
shaping the innate immune response in primates [52].
It would be interesting to investigate roles for BANCR
with this in mind.
TE-initiated lncRNAs as cancer-specific markers
There are many examples of TE-initiated RNAs with po-
tential roles in cancer or which are preferentially
expressed in malignant cells but for which a direct onco-
genic function has not yet been demonstrated. Still, such
transcripts may underlie a predisposition for transcrip-
tion of specific groups of LTRs/TEs in particular malig-
nancies and therefore function as a marker for a cancer
or cancer subtype. Since these events potentially do not
confer a fitness advantage for the cancer cell, they are
not “exaptations” but “nonaptations” [4].
One of these is a very long RNA initiated by the anti-
sense promoter of an L1PA2 element as reported by
Tufarelli’s group and termed LCT13 [172, 173]. EST evi-
dence indicates splicing from the L1 promoter to the
GNTG1 gene, located over 300 kb away. The tumor sup-
pressor gene, tissue factor pathway inhibitor 2, (TFPI-2),
which is often epigenetically silenced in cancers [174], is
antisense to LCT13 and it was shown that LCT13 tran-
script levels are correlated with down regulation of
TFPI-2 and associated with repressive chromatin marks
at the TFPI-2 promoter [172].
Gibb et al. analyzed RNA-Seq from colon cancers and
matched normal colon to find cancer-associated
lncRNAs and identified an RNA promoted by a solitary
MER48 LTR, which they termed EVADR, for Endogen-
ous retroviral-associated ADenocarcinoma RNA [175].
Screening of data from The Cancer Genome Atlas
(TCGA) [176] showed that EVADR is highly expressed
in several types of adenocarcinomas, it is not associated
with global activation of MER48 LTRs across the gen-
ome and its expression correlated with poorer survival
[175]. In another study, Gosenca et al. used a custom
microarray to measure overall expression of several
HERV groups in urothelial carcinoma compared to nor-
mal urothelial tissue and generally found no difference
[111]. However, they found one full-length HERV-E
element, located in the antisense direction in an intron
of the PLA2G4A gene that is transcribed in urothelial
carcinoma and appears to modulate PLA2G4A expres-
sion, thereby possibly contributing to carcinogenesis, al-
though the mechanism is not clear.
By mining long nuclear RNA datasets from ENCODE
cell lines, normal blood and Ewing sarcomas, one group
identified over 2000 very long (~50–700 kb) non coding
transcripts termed vlincRNAs [142]. They found the
promoters for these vlincRNAs to be enriched in LTRs,
particularly for cell type-specific vlincRNAs, and the
most common transcribed LTR types varied in different
cell types. Moreover, among the datasets examined, they
reported that the number of LTR-promoted vlincRNAs
correlated with degree of malignant transformation,
prompting the conclusion that LTR-controlled vlincR-
NAs are a “hallmark” of cancer [142].
In a genome-wide CAGE analysis of 50 hepatocellular
carcinoma (HCC) primary samples and matched non-
tumor tissue, Hashimoto et al. found that many LTR-
promoted transcripts are upregulated in HCC, most of
these apparently associated with non-coding RNAs as
the CAGE peaks in the LTRs are far from annotated
protein coding genes [177]. Similar results were found in
mouse HCC. Among the hundreds of human LTR
groups, they found the LTR-associated CAGE peaks to
be significantly enriched in LTR12C (HERV9) LTRs and
mapped the common TSS site within these elements,
which agrees with older studies on TSS mapping of this
ERV group [178]. Moreover, this group reported that
HCCs with highest LTR activity mostly had a viral
(Hepatitis B) etiology, were less differentiated and had
higher risk of recurrence [177]. This study suggests
widespread tissue-inappropriate transcriptional activity
of LTRs in HCC.
LTR12s as flexible promoters in cancer and normal tissues
Most recent human ERV LTR research has been fo-
cused on HERV-H (LTR7/7Y/7B/7C) due to roles for
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HERV-H/LTR7-driven RNAs in pluripotency [56–58,
60, 179, 180] or on the youngest HERV group,
HERV-K (LTR5/5Hs), due to its expression in early
embryogenesis [181–183], coding capacity of some
members [30, 184] and potential roles for its proteins
in cancer and other diseases [30–33, 185]. LTR12s
(including LTR12B,C,D,E and F subtypes), which are
the LTRs associated with the HERV-9 group [186],
are generally of similar age to HERV-H [187] but are
much more numerous than HERV-H or HERV-K,
with solitary LTRs numbering over 6000 (Table 1).
There are several examples of LTR12s providing pro-
moters for coding genes or lncRNAs in various normal
tissues [63, 188–191]. LTR12s, particularly LTR12C, are
longer and more CpG rich than most other ERV LTRs,
possibly facilitating development of diverse inherent
tissue-specificities and flexible combinations of TF bind-
ing sites, which may be less probable for other LTR types.
For example, the consensus LTR7 (HERV-H) is 450 bp
whereas LTR12C (of similar age) is 1577 bp [114], which
is usually long for retroviral LTRs. As noted above, LTR12
elements are among the most enriched LTR types acti-
vated as promoters in HCC [177] and appear to be the
most active LTR type in K562 cells [142]. It is important
to point out, however, that only a very small fraction of
genomic LTR12 copies are transcriptionally active in any
of these contexts, so general conclusions about activity of
‘a family of LTRs’ should be made with caution.
A number of other recent investigations on LTR12-
driven chimeric transcription have been published. One
study specifically screened for and detected numerous
LTR12-initiated transcripts in ENCODE cell lines, some
of which extend over long genomic regions and emanate
from bidirectional promoters within these LTRs [192].
The group of Dobbelstein discovered that a male germ
line-specific form of the tumor suppressor TP63 gene is
driven by an LTR12C [190]. Interestingly, they found
that this LTR is silenced in testicular cancer but reacti-
vated upon treatment with histone deacetylase inhibitors
(HDACi), which also induces apoptosis [190]. In follow-
up studies, this group used 3’ RACE to detect more
genes controlled by LTR12s in primary human testis and
in the GH testicular cancer cell line and reported hun-
dreds of transcripts, including an isoform of TNFRSF10B
which encodes the death receptor DR5 [193]. As with
TP63, treating GH or other cancer cell lines with HDAC
inhibitors such as trichostatin A activated expression of
the LTR12-driven TNFRSF10B and some other LTR12-
chimeric transcripts and induced apoptosis [193, 194].
Therefore, in some cases, LTR-driven genes can have a
proapoptotic role. In accord with this notion is a study
reporting that LTR12 antisense U3 RNAs were
expressed at higher levels in non-malignant versus ma-
lignant cells [195]. It was proposed that the antisense
U3 RNA may act as a trap for the transcription factor
NF-Y, known to bind LTR12s [196], and hence partici-
pate in cell cycle arrest [195].
Chromosomal translocations involving TEs in cancer
Activation or creation of oncogenes via chromosomal
translocations most commonly involves either the fusion
of two coding genes or juxtaposition of new regulatory
sequences next to a gene, resulting in oncogenic effects
due to ectopic expression [197]. One might expect some
of the latter cases to involve TE-derived promoters/en-
hancers but, to date, there are very few well-documented
examples of this mechanism in oncogenesis. The ETS
family member ETV1 (ETS variant 1) is a transcription
factor frequently involved in oncogenic translocations,
particularly in prostate cancer [198]. Although not a
common translocation, Tomlins et al. identified a pros-
tate tumor with the 5’ end of a HERV-K (HML-2) elem-
ent on chromosome 22q11.23 fused to ETV1 [199]. This
particular HERV-K element is a complex locus with two
5’ LTRs and is quite highly expressed in prostate cancer
[200]. Indeed, while a possible function is unknown, this
HERV-K locus produces a lncRNA annotated as PCAT-
14, for prostate cancer–associated ncRNA transcript-14
[201]. In the HERV-K-ETV1 fusion case, the resultant
transcript (Genbank Accession EF632111) initiates in
the upstream 5’LTR, providing evidence that the LTR
controls expression of ETV1.
The fibroblast growth factor receptor 1 (FGFR1) gene
on chromosome 8 is involved in translocations with at
least 14 partner genes in stem cell myeloproliferative
disorder and other myeloid and lymphoid cancers [202].
One of these involves a HERVK3 element on chromo-
some 19 and this event creates a chimeric ORF with
HERVK3 gag sequences [203]. While it was reported
that the LTR promoter may contribute to expression of
the fusion gene [203], no supporting evidence was pre-
sented. Indeed, perusal of public expression data
(Expressed sequence tags) from a variety of tissues indi-
cates that the HERVK3 element on chromosome 19 is
highly expressed, but from a non-ERV promoter just up-
stream (see chr19:58,305,253–58,315,303 in human hg38
assembly). Therefore, there is little current evidence for
LTR/TE promoters playing a role in oncogene activation
via chromosomal translocations or rearrangements.
Models for onco-exaptation
The aforementioned cases of onco-exaptation are a dis-
tinct mechanism by which proto-oncogenes become
oncogenic. Classical activating mutations within TEs
may also lead to transcription of downstream oncogenes
but we are unaware of any evidence for DNA mutations
resulting in LTR/TE transcriptional activation, including
cases where local DNA was sequenced [38] (unpublished
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results). Thus, it is important to consider the etiology
through which LTRs/TEs become incorporated into new
regulatory units in cancer. The mechanism could pos-
sibly be therapeutically or diagnostically important and
perhaps even model how TEs influence genome regula-
tion in evolutionary time.
In some of the above examples, there is no or very lit-
tle detectable transcription from the LTR/TE in any cell
type other than the cancer type in which it was reported,
suggesting the activity is specific to a particular TE in a
particular cancer. In other cases, CAGE or EST data
show that the LTR/TE can be expressed in other normal
or cancer cell types, perhaps to a lower degree. Hence
the term “cancer-specific” should be considered a rela-
tive one. Indeed, the idea that the same TE-promoted
gene transcripts occur recurrently in tumors from inde-
pendent individuals is central to understanding how
these transcripts arise. Below we present two models
that may explain the phenomenon of onco-exaptation.
The De-repression model
Lamprecht and co-workers proposed a ‘De-repression
model’ for the LTR driven transcription of CSF1R [204].
The distinguishing feature of this model is that onco-
exaptations arise deterministically, as a consequence of
molecular changes that occur during oncogenesis,
changes which act to de-repress LTRs or other TEs
(Fig. 4). It follows that ‘activation’ of normally dormant
TEs/LTRs could lead to robust oncogene expression. In
the CSF1R case, the THE1B LTR, which promotes
CSF1R in HL, contains binding sites for the transcription
factors Sp1, AP-1 and NF-kB, each of which contributes
to promoter activity in a luciferase reporter experiment
[113]. High NF-kB activity, which is known to be up-
regulated in HL, loss of the epigenetic corepressor
CBFA2T3 as well as LTR hypomethylation all correlated
with CSF1R-positive HL driven by the LTR [113]. Under
the de-repression model, the THE1B LTR is repressed by
default in the cell but under a particular set of
Fig. 4 De-repression model for onco-exaptation. In the normal or pre-malignant state TEs (grey triangles) are largely silenced across the genome.
There is low transcriptional activity to produce long non-coding RNA (orange box), or express coding genes in the case of evolutionary exaptations
(not shown). The example proto-oncogene (green box) is under the regulatory control of its native, restrictive promoter. During the process of
transformation and/or oncogenesis, a change in the molecular state of the cell occurs leading to loss of TE repressors (black circles), i.e. DNA
hypomethylation, loss of transcriptional or epigenetic repressive factors. The change could also be accompanied by a change/gain in activating factor
activities (red and purple shapes). Together these de-repression events result in higher TE promoter activity (orange triangles) and more TE-derived
transcripts based on the factors that become deregulated. Oncogenic activation of proto-oncogenes is a consequence of a particular molecular milieu
that arises in the cancerous cells
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conditions (gain of NF-kB, loss of CBFA2T3, loss of
DNA methylation) the LTR promoter is remodeled into
an active state [204]. More generally, the model proposes
that a particular LTR activation is a consequence of the
pathogenic or disrupted molecular state of the cancer
cell. In a similar vein, Weber et al. proposed that the L1-
driven transcription of MET arose as a consequence of
global DNA hypomethylation and loss of repression of
TEs in cancer [124].
The LOR1a-IRF5 onco-exaptation in HL [117] can be
interpreted using a de-repression model. An interferon
regulatory factor binding element site was created at the
intersection of the LOR1a LTR and genomic DNA. In
normal and HL cells negative for LOR1a-IRF5, the LTR
is methylated and protected from DNAse digestion, a
state that is lost in de-repressed HL cells. This transcrip-
tion factor-binding motif is responsive to IRF5 itself and
creates a positive feedback loop between the IRF5 and
the chimeric LOR1a-IRF5 transcript. Thus epigenetic
de-repression of this element may reveal an oncogenic
exploitation, resulting in high recurrence of LOR1a LTR-
driven IRF5 in HL [117].
A de-repression model explains several experimental
observations, such as the necessity for a given set of fac-
tors to be present (or absent) for a certain promoter to
be active, especially when those factors differ between
cell states. Indeed, experiments probing the mechanism
of TE/LTR activation have used this line of reasoning,
often focusing on DNA methylation [113, 117, 125, 129].
The limitation of these studies is that they fail to deter-
mine if a given condition is sufficient for onco-
exaptation to arise. For instance, the human genome
contains >37,000 THE1 LTR loci (Table 1), and indeed
this set of LTRs is generally more active in HL cells
compared to B-cells as would be predicted [113] (un-
published results). The critical question is why particu-
lar THE1 LTR loci, such as THE1B-CSF1R, are
recurrently de-repressed in HL, yet thousands of hom-
ologous LTRs are not.
The Epigenetic Evolution model
A central premise in the TE field states that TEs can be
beneficial to a host genome since they increase genetic vari-
ation in a population and thus increase the rate at which
evolution (by natural selection) occurs [62, 205, 206]. The
epigenetic evolution model for onco-exaptation (Fig. 5)
draws a parallel to this premise within the context of
tumor evolution.
Key to the epigenetic evolution model is that there is
high epigenetic variance, both between LTR loci and at
the same LTR locus between cells in a population. This
epigenetic variance fosters regulatory innovation, and in-
creases during oncogenesis. In accord with this idea are
several studies showing that DNA methylation variation,
or heterogeneity, increases in tumor cell populations and
this isn’t simply a global hypomethylation relative to
normal cells [207–209] (reviewed in [210]). In contrast
to the de-repression model, a particular pathogenic mo-
lecular state is not sufficient or necessary for TE-driven
transcripts to arise; instead the given state only dictates
which sets of TEs in the genome are permissive for tran-
scription. Likewise, global de-repression events, such as
DNA hypomethylation or mutation of epigenetic regula-
tors, are not necessary, but would increase the rate at
which novel transcriptional regulation evolves.
Underpinning this model is the idea that LTRs are
highly abundant and self-contained promoters dispersed
across the genome that can stochastically initiate low or
noisy transcription. This transcriptional noise is a kind
of epigenetic variation and thus contributes to cell-cell
variation in a population. Indeed, by re-analyzing CAGE
datasets of retrotransposon-derived TSSs published by
Faulkner et al. [73], we observed that TE-derived TSSs
have lower expression levels and are less reproducible be-
tween biological replicates, compared to non-TE pro-
moters (unpublished observations). During malignant
transformation, TFs can become deregulated and genome-
wide epigenetic perturbations occur [94, 98, 211] which
would change the set of LTRs that are potentially active as
well as possibly increasing the total level of LTR-driven
transcriptional noise. Up-regulation of specific LTR-driven
transcripts would initially be weak and stochastic, from
the set of permissive LTRs. Those cells gaining an LTR-
driven transcript which confers a growth advantage would
then be selected for, and the resultant oncogene expres-
sion would increase in the tumor population as that epial-
lele increases in frequency, in a similar fashion as
proposed for the epigenetic silencing of tumor suppressor
genes [95, 99, 100]. Notably, this scenario also means that
within a tumor, LTR-driven transcription would be subject
to epigenetic bottleneck effects as well, and that transcrip-
tional LTR noise can become “passenger” expression sig-
nals as the cancer cells undergo somatic, clonal evolution.
It may be counter-intuitive to think of evolution and
selection as occurring outside the context of genetic
variation, but the fact that both genetic mutations and
non-genetic/epigenetic variants can contribute to somatic
evolution of a cancer is becoming clear [209, 212–215].
Epigenetic information or variation by definition is trans-
mitted from mother to daughter cells. Thus, in the specific
context of a somatic/asexual cell population such as a
tumor, this information, which is both variable between
cells in the population and heritable, will be subject to
evolutionary changes in frequency. DNA methylation in
particular has a well-established mechanism by which in-
formation (mainly gene repression) is transmitted epige-
netically from mother to daughter cells [216] and DNA
hypomethylation at LTRs often correlates with their
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Fig. 5 Epigenetic evolution model for onco-exaptation. In the starting cell population there is a dispersed and low/noisy promoter activity at TEs
(colored triangles) from a set of transcriptionally permissive TEs (grey triangles). TE-derived transcript expression is low and variable between cells.
Some transcripts are more reliably measurable (orange box). Clonal tumor evolutionary forces change the frequency and expression of TE-derived
transcripts by homogenizing epialleles and use of TE promoters (highlighted haplotype). A higher frequency of ‘active’ TE epialleles at a locus results in
increased measurable transcripts initiating from that position. TE epialleles that promote oncogenesis, namely onco-exaptations, can be selected for
and arise multiple times independently as driver epialleles, in contrast to the more dispersed passenger epialleles, or “nonaptations”
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expression [113, 117, 217]. Thus, this model suggests that
one important type of “epigenetic variant” or epiallele is
the transcriptional status of the LTR itself, since the
phenotypic impact of LTR transcription may be high in
onco-exaptation. Especially in light of the fact that large
numbers of these highly homologous sequences are
spread across the genome, epigenetic variation, and pos-
sibly selection, at LTRs creates a fascinating system by
which epigenetic evolution in cancer may occur.
Conclusions
Here we have reviewed the growing number of exam-
ples of LTR/TE onco-exaptation. Although such TEs
have the potential to be deleterious by contributing to
oncogenesis if transcriptionally activated, their fixation
in the genome and ancient origin suggests that their
presence is not subject to significant negative selection.
This could be due to the low frequency of onco-
exaptation at a particular TE locus and/or to the fact
that cancer is generally a disease that occurs after the
reproductive years. However, it is generally assumed
that negative selection is the reason why TEs are under-
represented near or within genes encoding develop-
mental regulators [218–220]. Similarly we hypothesize
that LTR/TE insertions predisposed to causing potent
onco-exaptations at a high frequency would also be de-
pleted by selective forces.
In this review we have also presented two models that
may explain such onco-exaptation events. These two
models are not mutually exclusive but they do provide
alternative hypotheses by which TE-driven transcription
may be interpreted. This dichotomy is possibly best ex-
emplified by the ERBB4 case (Fig. 1e) [129]. There are
two LTR-derived promoters which result in aberrant
ERBB4 expression in ALCL. From the de-repression
model viewpoint, both LTR elements are grouped MLT1
(MLT1C and MLT1H) and thus this group can be inter-
preted as de-repressed. From the epigenetic evolution
model viewpoint, this is convergent evolution/selection
for onco-exaptations involving ERBB4.
Through application of the de-repression model, TE-
derived transcripts could be used as a diagnostic marker
in cancer. If the set of TE/LTR derived transcripts are a
deterministic consequence of a given molecular state, by
understanding which set of TEs correspond to which
molecular state, it might be possible to assay cancer
samples for functional molecular phenotypes. In HL for
example, CSF1R status is prognostically important [115]
and this is dependent on the transcriptional state of a
single THE1B. HL also has a specific increase in THE1
LTR transcription genome-wide (unpublished observa-
tions). Thus, it’s reasonable to hypothesize that the prog-
nostic power can be increased if the transcriptional
status of all THE1 LTRs is considered. A set of LTRs can
then be interpreted as an in situ ‘molecular sensor’ for
aberrant NF-kB function in HL/B-cells for instance.
The epigenetic evolution model proposes that LTR-
driven transcripts can be interpreted as a set of epimuta-
tions in cancer, similar to how oncogenic mutations are
analyzed. Genes that are recurrently (and independently)
onco-exapted in multiple different tumors of the same
cancer type may be a mark of selective pressure for ac-
quiring that transcript. This is distinct from the more di-
verse/noisy “passenger LTR” transcription occurring
across the genome. These active but “passenger LTRs”
may be expressed to a high level within a single tumor
population due to epigenetic drift and population bot-
tlenecks but would be more variable across different tu-
mors. Thus analysis of recurrent and cancer-specific
TE-derived transcripts may enrich for genes of signifi-
cance to tumor biology.
While we focused in this review on TE-initiated tran-
scription in cancer, many of the concepts presented here
can be applied to other regulatory functions of TEs such
as enhancers, insulators, or repressors of transcription.
Although less straightforward to measure, it is probable
that perturbations to such TE regulatory functions con-
tribute to some malignancies. Furthermore, several
studies have shown that TEs play substantial roles in
cryptic splicing in humans [221–223] and thus may be
a further substrate of transcriptional innovation in can-
cer, particularly since DNA methylation state can affect
splicing [224].
Regardless of the underlying mechanism, onco-
exaptation offers a tantalizing opportunity to model
evolutionary exaptation. Specifically, questions such as
“How do TEs influence the rate of transcriptional/regu-
latory change?” can be tested in cell culture experi-
ments. As more studies that focus on regulatory
aberrations in cancer are performed in the coming
years, we predict that this phenomenon will become in-
creasingly recognized as a significant force shaping
transcriptional innovation in cancer. Moreover, we
propose that studying such events will provide insight
into how TEs have contributed to reshaping transcrip-
tional patterns during species evolution.
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